<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04573179</url>
  </required_header>
  <id_info>
    <org_study_id>AF/SQ-05/30</org_study_id>
    <nct_id>NCT04573179</nct_id>
  </id_info>
  <brief_title>Effectiveness of 68Ga-PSMA PET/MRI for Improving the Detection of csPCa in Lesions With PI-RADS Score 3</brief_title>
  <official_title>Effectiveness of 68Ga-PSMA PET/MRI for Improving the Detection of Clinical Significant Prostate Cancer in Lesions With Prostate Imaging Reporting and Data System Score 3</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to explore the effectiveness of 68Ga-PSMA PET/MRI for improving&#xD;
      the detection of csPCa in lesions with PI-RADS score 3. This study is a prospective,&#xD;
      observational study, single-center research. After recruiting patients who are suspected&#xD;
      prostate cancer with a mpMRI PI-RADS version2 score of 3 and willing to perform prostate&#xD;
      biopsy to identify the diagnosis, 68Ga-PSMA PET/MRI will be performed. Lesions will be&#xD;
      reaccessed based on PET/MRI findings and compared with the pathological results.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2020</start_date>
  <completion_date type="Anticipated">July 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>detection rate</measure>
    <time_frame>one year</time_frame>
    <description>detection rate of csPCa</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>detection rate</measure>
    <time_frame>one year</time_frame>
    <description>detection rate of non-csPCa</description>
  </secondary_outcome>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Prostatic Neoplasms</condition>
  <eligibility>
    <study_pop>
      <textblock>
        community residents&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  males over 18 years old suspected for prostate cancer&#xD;
&#xD;
          -  serum PSA between 4ng/ml and 20ng/ml in recent two months&#xD;
&#xD;
          -  mpMRI PI-RADS version2 scores 3 in recent two months&#xD;
&#xD;
          -  willing to undertake prostate biopsy&#xD;
&#xD;
          -  no evidence of non-cancerous factors interfere PSA level, such as catheter insertion,&#xD;
             bladder stones, urinary tract infections or drug (e.g. finasteride)&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  history of prostate biopsy or other operations&#xD;
&#xD;
          -  history of prostate cancer associated treatment&#xD;
&#xD;
          -  contraindications for MRI or PET examination (e.g. claustrophobia, pacemakers, hip&#xD;
             metal implants, hyperglycemia, glomerular filtration rate less than 50 ml/min)&#xD;
&#xD;
          -  not suitable for prostate biopsy (e.g. coagulation dysfunction, skin infection at&#xD;
             perineal puncture site)&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hongqian Guo</last_name>
    <phone>13605171690</phone>
    <phone_ext>13605171690</phone_ext>
    <email>dr.ghq@nju.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Urology, Drum Tower Hospital, Medical School of Nanjing University, Institute of Urology, Nanjing University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jingyan Shi, MD</last_name>
      <phone>18260098653</phone>
      <phone_ext>18260098653</phone_ext>
      <email>18260098653@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 28, 2020</study_first_submitted>
  <study_first_submitted_qc>September 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2020</study_first_posted>
  <last_update_submitted>September 28, 2020</last_update_submitted>
  <last_update_submitted_qc>September 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School</investigator_affiliation>
    <investigator_full_name>Hongqian Guo</investigator_full_name>
    <investigator_title>Executive officer of Department of Urology, Drum Tower Hospital, Medical School of Nanjing University, Institute of Urology, Nanjing University</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

